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Edited by Judit Ova´diAbstract A peptide was designed from reactive site loop struc-
ture of a1 Antitrypsin Portland known as a1 PDX as a novel
mini-PDX inhibitor of furin. The sequence was derived from
(367–394) that contains the crucial furin cleavage motif RIPR382.
A P3 mutant replacing Ile380 by Leu was prepared as a ﬁrst model
peptide. A Cys residue was inserted at each terminal of the pep-
tide for purpose of cyclisation which was accomplished by air
or iodine-induced oxidation. This mini-PDX peptide both cyclic
and acyclic form inhibited in vitro furin activity (IC50 in nM)
when measured against either substrates Boc-RVRRMCA or
QVEGF-C [Abz-QVHSIIRRSLP-Y(NO2)-A-CONH2, Abz =
2-amino benzoic acid and Y(NO2) = 3-nitro tyrosine], latter
being derived from vascular endothelial growth factor-C
(VEGF-C) processing site. The geometrically constrained struc-
ture mimicking PDX reactive loop is crucial for enzyme inhibi-
tion. Our study further revealed that both mini-PDX peptides
inactivate furin in a slow tight binding manner, with disulﬁde-
bridged cyclic form being slightly more potent. Unlike PDX,
these peptides inhibit furin via a diﬀerent mechanistic pathway.
The study provides an alternate strategy for development of eﬃ-
cient peptide-based inhibitors of Proprotein Convertases includ-
ing furin.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Furin is a Ca2+-dependent cellular endoprotease that acti-
vates a large number of precursor proteins in secretory path-
way compartments [1,2]. This endoprotease is a key member
of subtilisin-kexin like mammalian proprotein convertases
(PCs) that cleave peptide bonds at the general motif R/K/H–
X–X/K/R–Rﬂ [3–5], where X = any amino acid usually not
Cys. Proteolytic processing of larger inactive precursor pro-
teins into functionally active smaller forms is an important cel-
lular event implicated in both normal and abnormal
pathophysiology. Over the years this hypothesis was well sub-
stantiated by numerous research publications [reviewed in 1,2].
Owing to this role, proteolytic enzymes remain in the forefront*Corresponding author. Fax: +1 613 761 4355.
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eases and metabolic disorders, even though several of these
proteases are also linked to normal development and impor-
tant physiological functions [2–4]. Thus design of potent and
selective protease inhibitors became a valuable research subject
in drug design and therapeutic applications. Several inhibitors
directed against host or foreign invading proteases have been
described in the literature for treatment of conditions such as
viral infections like AIDS, inﬂammatory diseases such as
chronic obstructive pulmonary disorder, prostate cancer and
others [6–8]. Furins critical role in many cellular events asso-
ciated with infections of HIV [9], SARS [10], Ebola [11], an-
thrax [12], and inﬂuenza [13] as well as cancer [14],
neurological dementia like Alzheimers disease [15] has made
this enzyme a therapeutic target. So far several furin inhibitors
have been reported that are either macromolecular proteins or
small molecule peptides to non-peptides [16]. Among them the
most potent is the bioengineered serpin protein a1-Antitrypsin
(AT) Portland (known as PDX) in which the reactive-centre
AlaP4–Ile–Pro–Met382(P1) sequence of a1 AT has been replaced
by furin motif Arg–Ile–Pro–Arg382ﬂ [17].
Despite several reports [16–19] not much success has been
achieved in designing small compound inhibitors of furin, that
are more attractive and useful as therapeutic agents because of
their stability and ease of accessibility. In this study, we devel-
oped a small peptide with the constrained reactive site loop
(RSL) structure of bioengineered serpin PDX as a modulator
of furin activity. It was already demonstrated that RSL of
all serpins are prime interactive domains responsible for their
protease inhibitory function [20–23]. In this paper, we describe
a linear and a corresponding disulﬁde-bridged cyclic peptide
variant based on RSL structure of a1-PDX and demonstrated
that both inhibit furin activity but with diﬀerential manner. To
our understanding, this is the ﬁrst report of a PC inhibitor
based on PDX loop structure. Previously, we reported that
chymotrypsin inhibitor 2 (CI-2) loop can be successfully used
to develop inhibitors of PCs [24].2. Materials and methods
All ﬂuoren-9-yl methoxycarbonyl (Fmoc) amino acids (L-conﬁgura-
tion), the coupling agents and organic solvents were purchased from
PE Applied Biosystems (Framingham, MA, USA), Calbiochem–
Novabiochem (San Diego, CA, USA), Chem-Impex International
(Wood Dale, IL, USA) and Aldrich Chemical Company (Milwaukee,
WI, USA). Recombinant furin enzyme and its substrate Boc-RVRR-
MCA (MCA = 4-methyl coumaryl-7-amide) used for kinetic studyblished by Elsevier B.V. All rights reserved.
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and Peptides International (Louisville, KY, USA), respectively. The
intramolecularly quenched ﬂuorogenic substrate, QVEGF-C [Abz-
QVHSIIRR227SLP-Y(NO2)-A-CONH2, MW 1703, Abz = 2-amino
benzoic acid and Y(NO2) = 3-nitro tyrosine] used in the present study
as a furin substrate was prepared as previously reported by us [25].
This peptide was derived from the physiological processing site
RR227SL of VEGF-C. Acetonitrile (ACN), 4-hydroxycinnamic acid,
HCl, triﬂouro ethanol (TFE), and all other reagents were purchased
from Sigma–Aldrich Company, Milwaukee, MI, USA.
2.1. Peptide synthesis
All peptides were synthesized as C-terminal amides on an automated
solid-phase peptide synthesizer (Pioneer, PE-Perseptive Biosytems Inc,
Framingham, MA, USA), following O-hexaﬂuoro-phospho-[7-aza-
benzotriazol-1-yl]-N,N,N 0,N 0-tetramethyluronium/di-isopropylethyl-
amine-mediated Fmoc chemistry using unloaded PAL-PEG
(polyamino linker polyethylene glycol) resin. The following amino acid
side chain protecting groups were used: t-butyloxycarbonyl (Boc) for
Lys; 2,2,4,6,7-pentamethyl dihydrobenzo furan-5-sulfonyl for Arg; t-
butyl for Ser, Thr, Asp and Tyr and trityl for His, Asn and Gln. A
deprotection cocktail (Reagent B) containing TFA, phenol, water
and triisopropylsilane was used and added to the peptide-bound resin
(5 ml) [6,19]. After 3 h of treatment at room temperature, the peptide
was recovered as described [6,19].
2.2. RP-HPLC protocol for peptide puriﬁcation
All peptides were puriﬁed by reversed-phase high-performance li-
quid chromatography (RP-HPLC, Rainin Dynamax) using a semi-pre-
parative column (CSC Exsil, C18, 25 cm · 1.0 cm, Chromatography
Specialty Co., St-Laurent, Quebec, Canada). The buﬀer system con-
sisted of an aqueous 0.1% (v/v) triﬂuoroacetic acid solution and an
organic phase of ACN also containing 0.1% (v/v) triﬂuoroacetic acid.
The elution was carried out by using a linear gradient from 15% to 60%
organic phase in 105 min following a 10-min isocratic step at 100%
aqueous phase (gradient A, semipreparative run) or from 0% to 60%
organic phase in 60 min (gradient A, for analytical run). The ﬂow rate
was adjusted to 2.0 or 1.0 ml/min, respectively, and the separation was
monitored by UV absorbance at 230 nm.
2.3. Amino acid analysis and N-terminal micro-sequencing
Quantitative amino acid analyses were performed following 24 h
hydrolysis in 6 N HCl in a sealed tube at 110 C in vacuo using the
ion chromatography system (ICS-2500, Dionex, Oakville, ON, Can-
ada) equipped with conductance detector [25]. The sequence of each
peptide was conﬁrmed by N-terminal microsequencing using Procise
instrument (PE Biosystem Inc, Framingham, MA, USA) and phenyl-
thio hydantoin chemistry [10].
2.4. Mass spectral analysis
The identity of each peptide was fully conﬁrmed by matrix-assisted
laser-desorption ionization-time of-ﬂight (MALDI-TOF) mass spec-
trometry (Voyageur-DE Pro, PE-Biosystems Inc, Framingham, MA,
USA) or surface enhanced laser desorption ionization time of ﬂight
(SELDI-TOF) (Ciphergen, CA, USA) on gold chips (http://
www.ciphergen.com) using 4-hydroxycinnamic acid or 1,2-dihydroxy
benzoic acid as energy absorbing matrix [10,19,26].
2.5. CD spectroscopy
All CD spectra were recorded in Jasco-810 spectropolarimeter (Eas-
ton, MD, USA) in 0.1-cm thick rectangular quartz cell in a total vol-
ume of 300 lL (100 lM ﬁnal concentrations) at 0.1 nm intervals from
185 to 240 nm wavelength at 25 C. Each spectrum was analyzed using
CD Estima and CONTIN software for estimation of various a-helix,
b-sheet, b-turn, and random structures (Softspec Co, NJ, USA). The
ﬁnal corrected CD spectra were obtained by subtracting the spectrum
obtained with control solvent from those of samples [26].
2.6. Cyclic peptide formation and characterization
For preparation of disulﬁde-bridged cyclic peptides, oxidation by air
or iodine solution was used. For air oxidation, air was continuously
bubbled through a dilute solution (100 ml, 0.015 lmol/ml)) of the pep-
tide (I) in aqueous ammonia, pH 8.0 at 25 C for overnight. Aliquotswere removed at various time intervals and analyzed by RP-HPLC.
For iodine oxidation, a minor modiﬁcation was made regarding the
concentration of the reagent used [27]. Thus 1-ml solution of peptide
(2.5 lmol/ml) in water:acetic acid (1:4) was treated at 25 C with iodine
solution (100 lL, 0.3 lmol/ml). The mixture was stirred for 3 h follow-
ing which 1 ml of 1 M sodium thiosulfate solution was added to termi-
nate the reaction. The mixture was concentrated by rotary evaporation
under reduced pressure and analyzed by RP-HPLC as described
above. All signiﬁcant peaks were collected and subjected to analysis
by MALDI-TOF mass spectrometry, amino acid analysis and N-ter-
minal microsequencing. The formation of cyclic peptide was conﬁrmed
by co-mass spectrometry with acyclic peptide, RP-HPLC as well as N-
terminal micro-sequencing and mass spectrometry following reduction
with tri(2-carboxyethyl)phosphine (TCEP) [28] and alkylation with
iodoacetamide as described in Focuse protein Reduction–Alkylation
kit (http://www.alphelys.com/site/fr/pKPEL_FOCUS_Prot_Alkyl.
htm).
2.7. Enzyme assay and kinetic evaluation
All in vitro enzyme studies were performed using initial rate and/or
end-time assays at room temperature in a ﬁnal volume of 100 ll in 96-
well ﬂat-bottom black plates (Micro-ﬂuor, Dynatec, Va, USA). The
buﬀer consisted of 25 mM Mes, 25 mM Tris and 2.5 mM CaCl2 (pH
7.4). Assays were performed using both Q-VEGF-C and Boc-
RVRR-MCA as substrates at two diﬀerent concentrations namely 10
and 30 lM of each. The release of highly ﬂuorescent 7-amino 4-methyl
coumarin (AMC) from Boc-RVRR-MCA and 2-amino benzoic acid
(Abz) containing N-terminal fragment from QVEGF-C were moni-
tored by a spectroﬂuorometer instrument (Perkin–Elmer model
LS50B) at excitation and emission wavelengths of 370 nm/460 nm
and 320 nm/420 nm, respectively. Recombinant furin (2 lL of 5-fold
diluted stock sample) from New England BioLabs, representing
0.8 U (unit) of activity, one U = amount of furin that will release
1 pmol of free AMC from Boc-RVRR-MCA (50 lM) was pre-incu-
bated for 30 min at 25 C with various concentrations of the mini-
PDX peptide. The ﬂuorogenic substrate Boc-RVRR-MCA or
QVEGF-C was then added and the released AMC or Abz-containing
peptide was measured. Ki (inhibition constant) values were derived
from Cornish–Bowden plots as described in [29]. For measurement
of both Ki and IC50 (the concentration necessary to achieve 50% inhi-
bition of enzymic activity) values, the inhibitor concentrations were
varied over a range wide enough to yield residual activities of 25–
75% of the control value [18,19,30].2.8. Digestion of QVEGF-C peptide by furin
QVEGF-C (10 lg) was incubated at 37 C with recombinant furin
(2 lL, 5-fold diluted of commercial stock as described above) in
25 mM Tris + 25 mM Mes + 2.5 mM CaCl2, pH 7.4 in a total volume
of 100 ll in the absence and presence of various amounts of cyclic and
acyclic mini-PDX peptides (I and II). Following 4 h digestion, the reac-
tion was terminated by adding glacial acetic (1 ll) and product ana-
lyzed by RP-HPLC chromatography.3. Results and discussion
3.1. Design of mini-PDX peptides
Sequence alignment of a number of known serpin inhibitors
near their reactive site cleavage loops (Table 1), revealed a
common resemblance of types of amino acids present at vari-
ous P and P 0 positions as indicated in the table. Of particular
signiﬁcance is the presence of near conserved alkyl side chain
containing hydrophobic amino acids at P6, P5, P4 and P
0
2 posi-
tions. It is further noted that in general they all contain nega-
tively charged Glu and/or Pro residues at positions between
P 03 and P
0
6. Moreover, the physiological serpin Spn4a and the
bioengineered serpin a1 PDX, the double mutant variant of
a1 AT (not shown in Table 1), both of which inhibit furin
activity also contain crucial P1 and P4 Arg residues. We
hypothesize that the reactive site loop domain of either of these
Table 1
Alignment of amino acid sequence of various naturally occurring serpins within their reactive site loop that contains the protease cleavage sites
(indicated by a vertical arrow)
P6P5 P4P3P2P1 P 01P
0
2P
0
3P
0
4P
0
5P
0
6
1: PLKVSAFIHK AFIEVNEEGT EAAAATGMAV RRKR
341 ﬂ AIMSPE EPIEFFADHP FTYVLVHQKD
2: DDLYVSDAFH KAFLEVNEEG SEAAASTAVV IAGR
426 ﬂ SLNPNR VTFKANRLFL VFIREVPLNT
3: APLKLSKAVH KAVLTIDEKG TEAAGAMFLE AIPM
382 ﬂ SIPPEV KFNKPFVFLM IEQNTKSPLF
4: RNLAVSQVVH KVVSDVFEEG TEASAATAVK ITLL
383 ﬂ SALVET RTIVRFNRPF LMIIVPTDTQ
5: EPLHVAQALQ KVKIEVNESG TVASSSTAVI VSAR
353 ﬂ MAPEEI IMDRPFLFVV RHNPTGTVLF
6: ESLKISQAVH AAHAEINEAG REVVGSAEAG VDAA
353 ﬂ SVSEEF RADHPFLFCI KHIATNAVLF
7: DPDLQVSAMQ HQTVLELTET GVEAAAASAI SVAR
59 ﬂ TLIVEE VEQPFLFVRW DQQHKFPVFM
Consensus motif: ab ve/c giujkl
Note. Abbreviations
1: d-SPN 4.1 (drosophila)
2: Antithrombin
3: h a1 AT (human alphal-antitrypsin)
4: Antichymotrypsin
5: PAI-1 (plasminogen activator inhibitor-1)
6: Ovalbomin
7: CI-2 (chymotrypsin inhibitor - 2)
a = conserved alkyl side chain containing aa
b = mostly Val/Ile/Gly(alkyl side chain containing aa)
v = either basic or branched alkyl side chain containing aa)
e = mostly alkyl side chain containing aa but can be other aa
/ = mostly Ala/Leu/Gly
c = mostly Arg or Leu/Ala
g = mostly Ser/Thr or small aa
I = conserved alkyl side chain containing aa
u,j,k,l = no apparent homology, but either Pro or Glu in majority of cases.
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tial attempt we used PDX loop structure with 30 amino acids
length. Our rationale for the design of small PDX-based furin
inhibitors is that apart from interaction with sheet structure
segments, the presentation and subsequent binding with furin
catalytic surface of reactive site loop of a1 PDX is equally
important for furin inhibitory property. Previous studies indi-
cated that this domain in a1 PDX is mostly located within the
residues (350–394) (Table 2a) [http://www-cryst.bioc.cam.a-
c.uk/~xypei/njg/antitrypsin.png]. In order to avoid synthetic
complications, we selected a slightly shorter (367–394) domain
within this segment for design of our mini-PDX peptides. Our
choice is based on studies involving 3D-model structure and
minimal sequence requirement for maintenance of conforma-
tional architecture of RSL [31]. Thus a 30-mer peptide from
residue (367–394) with Ile380 (P3) substituted by Leu and
having two terminal Cys residues was designed (Table 2b).
Two added Cys residues allowed the formation of a disulﬁde-
bridge cyclic ring system that can mimic the loop structure of
PDX. The rationale for mutating the Ile380 by Leu is based onTable 2a
Amino acid sequence of human alpha-antitrypsin double mutant variant cal
1 MPSSVSWGIL LLAGLCCLVP
41 DQDHPTFNKI TPNLAEFAFS
81 IATAFAMLSL GTKADTHDEI
121 QELLRTLNQP DSQLQLTTGN
161 LYHSEAFTVN FGDTEEAKKQ
201 DRDTVFALVN YIFFKGKWER
241 KVPMMKRLGM FNIQHCKKLS
281 EGKLQHLENE LTHDIITKFL
321 YDLKSVLGQL GITKVFSNGA
361 VLTIDEKGTE AAGAMFLERI
401 QNTKSPLFMG KVVNPTQK
Note. Residues in regular bold are those mutated from wild type sequence, it
the sequence of reactive site loop of PDX Bold italics show the terminal resobservation that furin seems to prefer branch alkyl rather
than straight chain containing amino acid at P3 position
[24,32].3.2. Synthesis and characterization of mini-PDX peptide (I)
Following synthesis, acyclic mini-PDX peptide (I) was puri-
ﬁed by RP-HPLC (Fig. 1, panel A). The peak eluting at
Rt = 50.04 min was collected and analyzed by analytical RP-
HPLC chromatogram to conﬁrm its homogeneity (Fig. 1, pa-
nel B). MALDI-TOF mass spectrum of this compound showed
a single peak at m/z 3337 (M + H)+ consistent with the calcu-
lated molecular weight of (I) (Fig. 1, panel D) compared to
that of crude material which exhibited multiple peaks along
with the correct mass (Fig. 1, panel C). The minor peak at
m/z 1668.5 was due to half the molecular weight (M + H)+/2.
The pure peptide was ﬁnally characterized by amino acid anal-
ysis, N-terminal micro-sequencing and by digestion experiment
with endoprotease Lys-C enzyme which cleaves peptide bonds
speciﬁcally after Lys residue [33]. The mass spectrum of crudeled a1-PDX
VSLAEDPQGD AAQKTDTSHH
LYRQLAHQSN STNIFFSPVS
LEGLNFNLTE IPEAQIHEGF
GLFLSEGLKL VDKFLEDVKK
INDYVEKGTQ GKIVDLVKEL
PFEVKDTEEE DFHVDQVTTV
SWVLLMKYLG NATAIFFLPD
ENEDRRSASL HLPKLSITGT
DLSGVTEEAP LKLSKAVHKA
PRﬂSIPPEVKF NKPFVFLMIE
alic residues represent signal peptide and segment underlined indicates
idues of the sequence selected for mini-PDX design.
Table 2b
Amino acid sequence of acyclic and cyclic mini-PDX variant peptides derived from segment (367–394) of human al PDX. Note the mutation of Ile by
Leu at P3 position shown in bold underlined
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respectively, for the fragments GTEAAGAMFLERIPRSIP-
PEVKFNK, GTEAAGAMFLERIPRSIPPEVK and FNK-
PF-Cys further conﬁrming the identity of the peptide which
is expected to be cleaved as shown by vertical arrows in Cys-
367KGTEAAGAMFLERLPRSIPPEVKFNKPF394-Cys.
The result also conﬁrmed the acyclic nature of the peptide indi-
cating that both terminal Cys residues are present in free
states.
3.3. Formation of S–S-bridged cyclic mini-PDX peptide (II)
Formation of intramolecular disulﬁde (–S–S–) bridge be-
tween N- and C-terminal Cys residues of (I) was accomplished
either by air or iodine oxidation. RP-HPLC chromatograms of
crude oxidized product following bubbling with air in alkaline
pH (8.0) at various times showed a gradual disappearance of
the peak for acyclic peptide (I) (Rt = 50.04 min) and appear-
ance of a new peak eluting earlier at Rt = 47.5 min correspond-
ing to the cyclic peptide (II) (not shown). Oxidation by iodine
was more eﬀective (>95% cyclisation in 3 h) than air (only
70% in 24 h) as analyzed by RP-HPLC. The purity of the
cyclic peptide (II) was further conﬁrmed by analytical RP-Fig. 1. RP-HPLC chromatograms of crude (A) and puriﬁed (B) mini-PDX p
(A) and (B) were performed on 100 and 10 lg of material using C18 semi-pr
described in Section 2. MALDI mass spectra (C) and (D) were recorded using
acid as matrix. Peaks at m/z 3337 and 1668.5 were attributed to (M + H)+ an
weight of mini-PDX (I).HPLC which showed a single peak eluting at Rt = 47.5 min
(not shown).
3.4. Characterization of cyclic peptide
The acyclic peptide I, (Rt = 50.04 min) displayed its correct
molecular ion peak at m/z 3337 in the mass spectrum while
the corresponding disulﬁde-bridge cyclic peptide II,
(Rt = 47.5 min) exhibited a strong peak at m/z 3335 commen-
surate with its calculated mass (Fig. 2A). The diﬀerence of
two mass units between the two peptides was further con-
ﬁrmed by recording a co-mass spectrum using a 1:1 mixture
of the two (Fig. 2B) which as expected showed a doublet of
peaks at m/z 3337 and 3335, corresponding to the presence
of two distinct peptides, acyclic (I) and S–S bridged cyclic
(II). Both peptides exhibited identical amino acid analysis.
Typically the data for acyclic peptide (I) is: Arg2 (2.4), Lys3
(3), Ala3 (3), Thr1 (0.7), Gly2 (2), Val1 (1.1), Ser1 (1.4), Pro4
(4.8), Ile1 (1), Leu2 (2), Met1 (0.9), Asn1 (0.9), Phe3 (3.4),
Glu3 (3.4), Cys2 (not detected) [The numbers in parenthesis
are those measured while the ones in subscript are the calcu-
lated values]. Final conﬁrmation for an internal S–S linkage
in (II) was obtained by comparison of mass spectral data ofeptide (I) and their MALDI mass spectra (C and D). Chromatograms
eparative or analytical column, respectively, with a solvent gradient as
1–2 ll of sample containing 5 lg peptide using 1,2-dihydroxy benzoic
d (M + H)+/2, respectively, in consistent with the calculated molecular
Fig. 2A. MALDI-TOF mass spectra of puriﬁed cyclic (II, top) and
acyclic (I, bottom) mini-PDX peptides showing their molecular
weights as 3335 (M + H)+ and 3337, respectively, in consistent with
the calculated values. The diﬀerence of 2 mass units in the molecular
ion peaks of the two peptides is in consistent with their structures and
conﬁrmed the formation of S–S bridge in (II).
Fig. 2B. MALDI-TOF co-mass spectrum of a mixture of acyclic (I)
and cyclic (II)) peptides (manually mixed in 1:1 molar ratio) indicating
the presence of two distinct peaks diﬀering in molecular weight by 2
mass units, conﬁrming the presence of two products of molecular
masses 3335 (M1) and 3337 (M2) for cyclic and acyclic peptides. Both
showed peaks at m/z = M-16 possibly due to the loss of terminal amide
NH2 group.
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with iodoacetamide with or without reduction with TCEP
[28]. SELDI-TOF mass spectrum of (I) (MW 3337) upon treat-
ment with alkylating agent iodoacetamide (I-CH2-CO-NH2)
without prior reduction exhibited strong peaks at m/z 3395
(an increase of 58 mass unit) for incorporation of one CH2–
CO–NH2 moiety (mono-alkylated product) and 3453 (an
increase of 2 · 58 mass units) for bis-alkylated product, respec-
tively. In contrast mass spectrum of (II) (MW 3335) upon
treatment with iodoacetamide remained unchanged. However
treatment of iodoacetamide following reduction with TCEP,
(II) showed in mass spectrum peaks at m/z 3393 and 3451for mono and bis-alkylated products, respectively. These re-
sults indicated that in (I) both Cys residues are in the free state
while in (II) they are interlinked by S–S bond. The above pro-
tocol consisting of a combination of mass spectroscopy as well
as alkylation and reductive alkylation provides an eﬃcient
method for detecting internal disulﬁde bridge in a peptide. Be-
sides iodoacetamide, other alkylating agents particularly those
with bulky groups such as iodopropionamide, iodoacetamido
ﬂuorescein or iodoadamantine can be explored. The latter
agents will lead to a large shift in molecular weight upon alkyl-
ation. Alternately formation of alkylated Cys-residues can be
detected by N-terminal microsequencing as well as by amino
acid analysis.3.5. Circular dichroism spectra and secondary structure
Secondary structure of acyclic mini-PDX peptide (I) was
ﬁrst investigated by circular dichroism spectra at neutral pH
in various solvent conditions of water, water:TFE (1:1) mix-
ture and TFE (Fig. 3). The measured secondary structural ele-
ments based on software analysis suggested that b-sheet
structure is most predominant in (I) in all solvent conditions
with no helix structure in water. However, addition of TFE
to water promotes helix structure mainly at the expense of ran-
dom structure indicating its propensity for adopting some heli-
cal conformation. Despite this observation, it is also evident
that (I) possesses mainly b-sheet structure in aqueous medium
of physiological pH. Similar observation was also noticed with
the cyclic peptide (II). This is signiﬁcant because of the role of
b-sheet structure in furin inhibition by complete PDX molecule
[17]. It may be mentioned that software analysis of CD spectra
is only approximate and provides a rough estimation of indi-
vidual secondary structural element.3.6. Eﬀects of cyclic and acyclic mini-PDX peptides on furin
digestion of QVEGF-C
In order to examine in vitro furin inhibition by mini-PDX
peptides, two substrates namely Boc-RVRRMCA and
QVEGF-C [Abz-QVHSIIRR227SLP-Y(NO2)-A-CONH2]
were selected. The latter, an intramolecularly quenched ﬂuoro-
genic (IQF) substrate contains the physiological furin activa-
tion site of human proVEGF-C, a potential marker of
tumorigenesis [25]. As shown by RP-HPLC analysis (Fig. 4, left
panel), addition of cyclic mini-PDX peptide (II) blocks furin-
mediated cleavage of QVEGF-C in a dose-dependent manner.
Thus in absence of (II), furin completely cleaves QVEGF-C
(Rt = 41.6 min) in 3 h at the correct physiological site leading
to two fragments, the N-terminal (NT) Abz-QVHSIIRR-OH
(Rt = 34.2 min, molecular weight = 1128) and the C-terminal
(CT) SLP-Y(NO2)-A-CONH2 (Rt = 37.1 min, molecular
weight = 595). The identity of above two fragments and the
undigested QVEGF-C peptide (molecular weight = 1703) were
fully conﬁrmed by mass spectral analysis of collected peaks
(Fig. 4, right panel) as well as by N-terminal microsequencing.
As shown in Fig. 4, 30 lM of (II) completely blocks furin-med-
iated cleavage of QVEGF-C, leading to the disappearance of
peaks at Rt = 34.2 and 37.1 min with concomitant increase in
intensity of undigested peptide peak at Rt 41.6 min. A similar
eﬀect is also noted with acyclic mini-PDX peptide (I) but with
less eﬃciency (not shown). It may be pointed out that unlike
PDX neither (I) nor (II) exhibited any signiﬁcant cleavages
by furin under the conditions used.
Fig. 3. Overlay of circular dichroism spectra of mini-PDX peptide (I) in water, water–TFE mixture (1:1) and TFE alone. The spectra were recorded
at room temperature in 1 ml quartz cell with 300 ll solution containing 300 lg of peptide. Each spectra were recorded three times, averaged and was
subtracted from that of blank solvent. Finally the spectra were analyzed by software programs Softsec (Estima and Contin) for secondary structural
contents (shown in the ﬁgure).
Fig. 4. RP-HPLC chromatograms (left) of 3 h digests of QVEGF-C (10 lg) by recombinant human furin (0.8 units, for details see Section 2) in the
absence and presence of various amounts cyclic mini-PDX peptide (II). Furin cleaves QVEGF-C Abz-QVHSIIRRﬂSLP-Y(NO2)-A-CONH2,
(Rt = 41.6 min, molecular weight = 1703) into amino terminal (NT) fragment, Abz-QVHSIIRR-OH (Rt = 34.2 min, molecular weight = 1128) and
carboxy terminal (CT) fragment SLP-Y(NO2)-A-CONH2 (Rt = 37.1 min, molecular weight = 595). The right panel shows the mass spectra of all
collected peaks that are consisted with their calculated masses.
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3.7.1. QVEGF-C as substrate. The comparative ability of
peptides (I) and (II) to inhibit cleavage of ﬂuorogenic substrate
QVEGF-C by furin was examined kinetically by ﬂuorescence
spectroscopy. As shown in Fig. 5, on line progress curves indi-
cated a slow binding inhibition of furin activity by both (I) and
(II) as measured by QVEGF-C. It is evident that during ﬁrst
20 min, there was nearly no inhibition even at 5 lM concentra-tion. In fact slight activation is noted during this period in
some cases. However, a longer incubation time such as
60 min, led to strong furin inactivation. In fact under the con-
dition used, between 1 and 2 lM of either (I) or (II) completely
blocks furin cleavage of QVEGF-C. The results indicated that
both (I) and (II) interact with furin in a similar manner requir-
ing a long incubation period for eﬀective complexation and
binding. End-time assay also showed a similar pattern of furin
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Fig. 5. Progress curves over a period of 3000 s (s) showing inhibition of furin activity in the presence of varying amounts of acyclic mini-PDX peptide
(I) (A) and corresponding cyclic mini-PDX peptide (II) (B). The enzymatic activity was measured against the intramolecularly quenched ﬂuorogenic
substrate QVEGF-C (10 lM) in 25 mM Tris + 25 mM Mes + 2.5 mM CaCl2, pH 7.4 as described in Section 2. The broken straight lines indicate
slopes corresponding to furin activity in the absence of any inhibitor.
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Fig. 6A. Bar graphs based on stop time assay showing time dependent
inhibitory eﬀects of mini-PDX peptides (I and II) against furin activity
as measured with QVEGF-C (10 lM) as a substrate. For each group
the extreme left bar represents 1 h incubation, middle bar 2 h
incubation and the right one 3 h incubation. The results were
accomplished using three independent experiments.
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Fig. 6B. Determination of IC50 values using Lineweaver–Burke plot
for inhibitory activity of mini-PDX peptides (I and II) towards furin as
measured with QVEGF-C substrate (10 lM). The data were compiled
from stop time assay following 3 h digestion of the substrate with furin
in the absence and presence of various concentrations of mini-PDX
peptides.
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were noticed. As indicated by bar graphs in Fig. 6A, activity
of furin is inhibited gradually by either (I) or (II) in a dose-
dependent manner following 1–3 h of incubation. The data
also indicates a time dependent inhibitory nature of the peptide
since more incubation time led to a more eﬀective furin inhibi-
tion. IC50 values based on Lineweaver–Burke plots using 3 h
incubation end time data (Fig. 6B) were estimated to be
731 ± 58 nM and 569 ± 62 nM, respectively for (I) and (II)
indicating that internal disulﬁde bond formation between the
two terminal Cys residues led to a marginal enhancement of
protease inhibitory action. It is expected that selection of amuch larger loop and or selected mutations within mini-
PDX may provide even more potent and selective furin inhib-
itors.
3.7.2. Boc-RVRR-MCA as substrate. When measured
against Boc-RVRR-MCA as a substrate, again both (I) and
(II) inhibit furin activity also in a slow binding in a manner
similar to that observed with QVEGF-C. As shown by pro-
gress curves in Fig. 7, acyclic peptide (I) appears to be slightly
more eﬀective inhibitor than the cyclic peptide (II). Thus while
0.375 lM of (I) is suﬃcient to fully block the cleavage of Boc-
RVRRMCA by furin, (II) required a slightly higher amount
(between 0.5 and 1 lM) for complete blockade of this cleavage.
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Fig. 7. Progress curves over a period of 7000 seconds (s) showing inhibition of furin activity in the absence and presence of varying concentrations of
acyclic mini-PDX peptide (I) and corresponding cyclic mini-PDX peptide (II). The enzymatic activity was measured against the ﬂuorogenic substrate
Boc-RVRR-MCA (25 mM) in 25 mM Tris + 25 mMMes + 2.5 mM CaCl2, pH 7.4 as described in Section 2. The broken straight lines indicate slopes
corresponding to furin activity in the absence of any inhibitor.
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cases while signiﬁcant inhibition of furin activity was only
noted following a longer period of incubation (>30 min).
These results indicate that furin-inhibitory action of mini-
PDX peptides may be dependent on the nature of the substrate
used. It may be noted that while QVEGF-C possesses both P
and P 0 residues to interact with furin, the peptide-MCA con-
tains P residues alone which may explain the observed diﬀer-
ences in potency of mini-PDX peptides in two cases.
However, other ﬂuorogenic substrates may be tested to con-
ﬁrm this observation.4. Conclusion
In summary, a novel peptide with strong furin-inhibitory
property was developed from the RSL structure of variant ser-
pin PDX. The peptide was designed from residue (367–394) in
both acyclic and disulﬁde-bridge cyclic forms encompassing
the furin cleavage site RIPR382. Both inhibited furin activity
with nano-molar eﬃciencies when measured with either a pep-
tide-MCA or an IQF peptide containing furin processing site
of VEGF-C – a key tumor indicator protein. In case of
QVEGF-C, the S–S bridged constrained cyclic peptide is a
more potent inhibitor than the corresponding acyclic peptide.
Using a variety of other IQF-peptides developed by us (6,
10, 25, 32), we are currently examining this notion. In addition
the comparative selectivity of inhibition is also under investiga-
tion. It may be pointed out that while PDX (a 418 amino acid
protein) inhibits furin activity in sub-nanomolar eﬃciency
when measured with peptide-MCA substrates such as
pyroGlu–Arg–Thr–Arg–Arg–MCA or Boc–Arg–Val–Arg–
Arg–MCA, our mini-PDX peptides are only eﬀective at com-
paratively higher concentration (10–100-fold). However to
our knowledge this is the ﬁrst demonstration of a peptide-
based inhibitor of furin derived from PDX sequence. The only
constraint used in this study namely S–S bridge did not signif-
icantly improved bioactivity, however other constraints
namely head–tail peptide linkage or use of suitable linker
may be employed and tested in future studies. The steps of
inactivation of furin by mini-PDX peptide are quite diﬀerentfrom that of complete PDX protein which forms a strong sta-
ble complex with the enzyme. The exact mechanism is not
clearly understood at this stage and requires further study.
This methodology could be expanded to other serpin struc-
tures for targeting various proteases including other members
of furin family [34]. In fact another model peptide based on
endogenous serpin inhibitor dSPN4.1 [23] of furin from dro-
sophila is currently under study in our laboratory. Moreover
other mini-PDX peptides containing various mutations at
reactive furin cleavage site are also being investigated for their
potency and selectivity of furin inhibition. In addition work
using various cell lines is in progress to examine the eﬃcacy
of our mini-PDX peptide in blocking furin activity in ex vivo
model.
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